Expanding R&D Programs, Clinical Trials, Drug Applications and Acquisitions, Advancing to Help Patients with Unmet Medical Needs - Research Report on Questcor, BioMarin, Vanda, Illumina and Theravance

NEW YORK, August 2, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Illumina Inc. (NASDAQ: ILMN), and Theravance Inc. (NASDAQ: THRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Questcor Pharmaceuticals, Inc. Research Report

On July 30, 2013, Questcor Pharmaceuticals, Inc. (Questcor) reported its Q2 2013 financial results, with GAAP net sales of $184.6 million, higher compared to $112.5 million in Q2 2012, primarily due to the expanded usage of H.P. Acthar Gel in treatment from dermatomyositis, polymyositis, systemic lupus erythematosus, and rheumatoid arthritis. The Company also said that the sales growth was due to increased prescriptions in treatment for nephrotic syndrome and multiple sclerosis. The Company's GAAP diluted EPS was $1.12 compared to $0.65 in Q2 2012. "Our commercial expansion effort continues, most recently driven by increasing usage of Acthar among rheumatologists," said Don M. Bailey, President and Chief Executive Officer of Questcor. "This rapid success has encouraged us to accelerate our entry into pulmonology, where we recently announced a pilot commercialization effort for respiratory manifestations of symptomatic sarcoidosis, a labeled indication for Acthar. Additionally, in the second quarter we acquired the rights to Synacthen, which will further expand our melanocortin peptide R&D program. This action provides us a platform for potential further U.S. growth and the initiation of international commercial activity for Synacthen and potentially for Acthar." The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-31/QCOR]

--

BioMarin Pharmaceutical Inc. Research Report

On July 25, 2013, BioMarin Pharmaceutical Inc. (BioMarin) reported its Q2 2013 financial results, with revenue growth of 10.3% YoY to $136.8. GAAP net loss was $21.5 million or $0.16 per diluted share, compared to GAAP net loss of $32.0 million or $0.27 per diluted share in Q2 2012. "In the second quarter, we continued to execute on our development goals as we head into the second half of the year," said Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin. "We made good progress in a number of important areas including commercial, R&D and regulatory." BioMarin reaffirmed its full-year 2013 guidance with total revenue expected in the range of $530 to $555 million. The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-31/BMRN]

--

Vanda Pharmaceuticals, Inc. Research Report

On July 29, 2013, Vanda Pharmaceuticals Inc. (Vanda) announced that its filing for a new drug application for tasimelteon has been accepted by the US Food and Drug Administration and granted a priority review classification. "We are extremely pleased that the FDA has granted tasimelteon priority review for the treatment of Non-24 in the totally blind," said Mihael H. Polymeropoulos, M.D., Vanda's President and Chief Executive Officer. "The agency's acceptance of the NDA and decision to place tasimelteon in a category of expedited review are important milestones for Vanda as we take another step toward our goal of providing patients with a treatment for Non-24." The Full Research Report on Vanda Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-31/VNDA]

--

Illumina Inc. Research Report

On July 23, 2013, Illumina Inc. (Illumina) announced the acquisition of Advanced Liquid Logic (ALL), a leading provider of liquid handling solutions. Illumina stated that the new, wholly owned subsidiary of Illumina developed a proprietary "digital microfluidics" technology based on electrowetting that precisely manipulates small droplets within a sealed disposable cartridge to perform complex laboratory protocols. "For our research customers, ALL's technology will further streamline the industry's simplest NGS workflow, while for clinical and applied markets, where ease of use and consistency are especially valued, it will allow us to offer integrated, end-to-end solutions," said Christian Henry, Senior Vice President and General Manager of Illumina's Genomic Solutions business. "ALL brings an impressive IP portfolio in digital microfluidics and a talented team with a track record of innovation." The Full Research Report on Illumina Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-31/ILMN]

--

Theravance Inc. Research Report

On July 25, 2013, Theravance Inc. (Theravance) reported its Q2 2013 financial results, with revenue of $1.3 million, slightly lower as compared to $1.4 million in Q2 2012, due to the termination of the Company's global collaboration arrangement with Astellas Pharma Inc. for the development and commercialization of VIBATIV. Net loss totaled $36.4 million or $0.37 per diluted share, compared with $37.1 million or $0.42 per diluted share in Q2 2012. Rick E Winningham, Theravance's Chief Executive Officer, said, "In the second half of 2013, we anticipate a number of significant events: the launch of BREO ELLIPTA in the U.S., a potential decision on RELVAR ELLIPTA in the EU, a PDUFA goal date in December 2013 for ANORO ELLIPTA, results from Phase 2 studies of TD-9855 and TD-4208 and potential completion of the separation into two companies. Overall, we believe Theravance is in a strong position, focusing on its strategy of advancing medicines in areas of unmet medical need." The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-31/THRX]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports